Safety of low-molecular-weight heparin in pregnancy: A systematic review

Thrombosis and Haemostasis

Volumn 81, Issue 5, 1999, Pages 668-672

  Sanson, Bernd Jan ^a,k   Lensing, Anthonie W A ^a   Prins, Martin H ^a   Ginsberg, Jeffrey S ^b   Barkagan, Zinoviy S ^c   Lavenne Pardonge, Edith ^d   Brenner, Benjamin ^e   Dulitzky, Mordechay ^f   Nielsen, Jørn D ^g   Boda, Zoltan ^l   Turi, Susanna ^h   Mac Gillavry, Melvin R ⁱ   Hamulyák, Karly ^l   Theunissen, Ingrid M ^d   Hunt, Beverley J ^j   Büller, Harry R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c ALTAI STATE MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e RAMBAM MEDICAL CENTER   (Israel)

^f SHEBA MEDICAL CENTER   (Israel)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ SLOTERVAART HOSPITAL   (Netherlands)

^j ST THOMAS HOSPITAL   (United Kingdom)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHOSPHOLIPID ANTIBODY; REVIPARIN; TINZAPARIN;

ALLERGIC REACTION; AUTOIMMUNE DISEASE; BLEEDING; BONE DENSITY; COMORBIDITY; COMPARATIVE STUDY; DRUG SAFETY; FEMALE; FETUS; FETUS DISEASE; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; MEDICAL RECORD; OSTEOPOROSIS; POPULATION RESEARCH; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

EID: 0032932342     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614550     Document Type: Review

References (33)

1. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995; 108: 305S-11S.
2. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
3. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-40.
4. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-3.
5. Flessa HC, Kapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol 1965; 93: 570-3.
6. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-73.
7. Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992; 116: 279-84.
8. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable-coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
9. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61: 197-203.
10. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170: 1315-20.
11. Dahlman TC, Hellgren MS, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol 1989; 161:420-5.
12. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332: 1374-6.
13. Kapsch D, Silver D. Heparin-induced thrombocytopenia with thrombosis and hemorrhage. Arch Surg 1981; 116: 1423-7.
14. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-70.
15. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
16. Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-6.
17. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 1988; 543: 65-72.
18. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
19. Monreal M, Lafoz E, Olive A, del RL, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
20. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171-4.
21. Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987; 57: 234.
22. Melissari E, Parker CJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1989; 62: 451-3.
23. Gillis S, Shushan A, Eldor A. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 1992; 39: 297-301.
24. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-6.
25. Gris JC, Neveu S, Tailland ML, Courtieu C, Mares P, Schved JF. Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost 1995; 73: 362-7.
26. Kiss H, Egarter C, Asseryanis E, Putz D, Kneussl M. Primary pulmonary hypertension in pregnancy: a case report. Am J Obstet Gynecol 1995; 172: 1052-4.
27. Theunissen I, Schlit A, Col De Beys C, Lavenne Pardonge E, Lierde van M. Hemostasis during pregnancy: physiological changes and effect of low dose aspirin and a low molecular weight heparin in high risk pregnancies. Am J Obstet Gynecol 1995; 172: 319.
28. Heligren M, Bremme K, Blomback M, Siegbahn A. Thromboprophylaxis with fragmin during pregnancy. Acta Obstet Gynecol Scand 1996; 75, Suppl. 162: 86.
29. Lee LH, Liauw PC, Ng AS. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement. Thromb Haemost 1996; 76: 628-30.
30. Boda Z, Laszlo P, Rejto L, Tornai I, Pfliegler G, Blasko G, Rak K. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Thromb Haemost 1996; 76: 128.
31. Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
32. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062-8.
33. Laskin C, Ginsberg JS, Farine D, Crowther M, Spitzer K, Soloninka C, Ryan G, Seaward G, Ritchie K. Low molecular weight heparin and ASA therapy in women with autoantibodies and unexplained recurrent fetal loss (U-RFL). Am J Obstet Gynecol 1997; 176: S125.